Qube Research & Technologies (QRT)’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-781	Closed	-$5K	–	3163
2022 Q3	$5K	Sell	781 -89	-10%	-$813	﹤0.01%	2406
2022 Q2	$9K	Buy	+870	New	+$11.7K	﹤0.01%	2331
2021 Q1	–	Sell	-1,082	Closed	-$676K	–	2549
2020 Q4	$676K	Buy	+1,082	New	+$491K	0.01%	1005

Other funds holding SGTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cercano Management Bellevue, Washington $2.32B AUM 30.12% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Qube Research & Technologies (QRT)'s SGTX Position: Q4 2022 in Review

Qube Research & Technologies (QRT) sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q4 2022, closing a stake of 781 shares — an estimated $5K sold.

Qube Research & Technologies (QRT) first reported a position in SGTX in Q4 2020 and held it in 3 quarters. The position peaked at $676K in Q4 2020. 32 funds tracked by Wall St. Rank hold SGTX as of Q4 2022.

Qube Research & Technologies (QRT) reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 781 Sigilon Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $5K.
Qube Research & Technologies (QRT) first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
Qube Research & Technologies (QRT)'s Sigilon Therapeutics, Inc. Common Stock position peaked at $676K in Q4 2020.
32 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q4 2022, filed 14 Feb 2023.